Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Saudi J Gastroenterol ; 24(1): 37-45, 2018.
Article in English | MEDLINE | ID: mdl-29451183

ABSTRACT

Background/Aim: Currently, it has been proposed that combination of 5-fluorouracil (5FU) with inhibitors of the mitogen-activated protein kinases (MAPKs) signaling pathway might enhance the efficacy of 5FU-based chemotherapy in colon cancer. Our study aimed to investigate an impact of TWIST1 silencing on the sensitivity of cancer cells to 5FU and selected MAPK inhibitors. Materials and Methods: The suppression of TWIST1 expression in human colon cancer HT29 and HCT116 cell lines was achieved by transduction with lentiviral vector carrying the TWIST1 silencing sequence (pLL3.7-sh TWIST1). The statistical calculation was performed with analysis of variance or Dunnett's test for comparison to control group. Paired Student's t-test was performed when two groups were analyzed. Results: Suppression of TWIST1 reduced the proliferation rate of colon cancer cells and enhanced their sensitivity to 5FU and MAPKs inhibitors. The sensitivity of HT29 cells to examined compounds was more dependent on TWIST1 expression level compared to HCT116 cells. The most noticeable effect of TWIST1 suppression on sensitivity of both colon cancer cell lines to combined treatment of 5FU and the MAPKs inhibitors was observed for inhibitors of p38α/ß and JNK1-3. We also noted that the suppression of TWIST1 significantly sensitized both cell lines to combined treatment of 5FU and Rac inhibitor. Conclusions: Our observations point to TWIST1 expression level as a marker of colon cancer sensitivity to combined treatment of 5FU and MAPKs inhibitors.


Subject(s)
Colonic Neoplasms/genetics , MAP Kinase Signaling System/drug effects , Nuclear Proteins/genetics , Protein Kinase Inhibitors/pharmacology , Twist-Related Protein 1/genetics , Cell Proliferation/drug effects , Cell Survival/drug effects , Colonic Neoplasms/drug therapy , Colonic Neoplasms/metabolism , Drug Resistance, Neoplasm/drug effects , Fluorouracil/pharmacology , Gene Expression Regulation, Neoplastic , Gene Silencing , HCT116 Cells , HT29 Cells , Humans , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Nuclear Proteins/metabolism , Protein Kinase Inhibitors/therapeutic use , Twist-Related Protein 1/metabolism
2.
Int Arch Allergy Immunol ; 172(1): 11-19, 2017.
Article in English | MEDLINE | ID: mdl-28219068

ABSTRACT

BACKGROUND: It is assumed that beside alterations in the filaggrin gene (FLG), disturbances within genes encoding other cornified envelope proteins are also involved in atopic dermatitis (AD). To identify new potential markers of AD, we studied the polymorphisms of genes encoding repetin (RPTN), cornulin (CRNN), and their expression in the skin of AD patients. METHODS: Polymorphisms in CRNN (rs941934), RPTN (rs284544, rs28441202, rs3001978, and rs12117644), and FLG mutations (R2447X, S3247X) were analyzed by TaqMan genotyping assay and by PCR-RFLP in the blood samples of 159 AD patients and 108 healthy subjects. The expression levels of CRNN and RPTN were determined by qRT-PCR in 34 AD skin samples (17 lesional and 17 nonlesional) and in 27 skin biopsies from healthy volunteers. The AD patients were recruited from the clinic of the university hospital between 2012 and 2014. RESULTS: CRNN rs941934 (A allele) was associated with AD (OR 2.095, p = 0.008), a severe course of disease (p = 0.041), elevated IgE levels (p = 0.047), eosinophilia (p = 0.018), and concomitant asthma (p = 0.004). The mRNA level of CRNN was decreased in the AD skin (p = 0.041). In the AD patients without FLG mutations, the CC genotype of RPTN rs3001978 was associated with AD (OR 0.39, p = 0.037), early age at onset (p = 0.033), pruritus (p = 0.021), severity of AD (p = 0.045), and concomitant asthma (p = 0.041). The elevated mRNA levels of RPTN in lesional (p < 0.001) and nonlesional (p = 0.017) AD skin were observed. CONCLUSIONS: The single-nucleotide polymorphisms of CRNN (rs941934) and RPTN (rs3001978, rs28441202) may contribute to AD development, but further studies on a larger group of AD patients are needed to verify this assumption.


Subject(s)
Dermatitis, Atopic/genetics , Genetic Predisposition to Disease , Membrane Proteins/genetics , Neoplasm Proteins/genetics , Polymorphism, Single Nucleotide/genetics , S100 Proteins/genetics , Adolescent , Adult , Child , Dermatitis, Atopic/pathology , Female , Filaggrin Proteins , Genetic Markers/genetics , Humans , Immunoglobulin E/blood , Male , Membrane Proteins/metabolism , Middle Aged , Neoplasm Proteins/metabolism , Poland , Risk Factors , S100 Proteins/metabolism , Skin/pathology , Young Adult
3.
Acta Derm Venereol ; 97(1): 36-41, 2017 01 04.
Article in English | MEDLINE | ID: mdl-27304082

ABSTRACT

Changes in the expression of cornified envelope (CE) proteins are thought to affect the development and course of atopic dermatitis (AD). The aim of this study was to examine the expression level of CE proteins in order to identify new molecular markers of the AD phenotype. Expression levels of CE proteins were evaluated in the skin of patients with AD (38 biopsies) and healthy subjects (26 biopsies). Levels of FLG, FLG2 and SPRR3 mRNAs and proteins were reduced in AD skin. Levels of LELP-1 and SPRR1A transcripts and proteins were significantly increased in AD skin. SPRR3v2 mRNA level in non-lesional AD skin correlated with severity of AD, and SPRR3 protein level in non-lesional AD skin correlated inversely with pruritus. FLG protein level in AD skin correlated inversely with severity of AD. These results point to SPRR3 as an important factor in AD and itch.


Subject(s)
Cornified Envelope Proline-Rich Proteins/genetics , Dermatitis, Atopic/genetics , Gene Expression , Adolescent , Adult , Biomarkers/metabolism , Biopsy , Case-Control Studies , Cornified Envelope Proline-Rich Proteins/metabolism , Dermatitis, Atopic/metabolism , Enzyme-Linked Immunosorbent Assay , Female , Filaggrin Proteins , Humans , Immunoglobulin E/blood , Intermediate Filament Proteins/genetics , Male , Middle Aged , Phenotype , Real-Time Polymerase Chain Reaction , S100 Proteins/genetics , Severity of Illness Index
4.
Int J Biochem Cell Biol ; 78: 268-278, 2016 09.
Article in English | MEDLINE | ID: mdl-27458056

ABSTRACT

The 5-fluorouracil (5FU)-based adjuvant chemotherapy improves the survival of patients with colorectal cancer, however the main obstacle affecting its effectiveness is a drug resistance. Our study aimed to investigate the impact of TWIST1 silencing on the sensitivity of cancer cells to 5FU. The suppression of TWIST1 expression in human colon cancer HT29 and HCT116 cell lines was achieved by transduction with lentiviral vector carrying the TWIST1 silencing sequence (pLL3.7-shTWIST1). The suppression of TWIST1 expression induced changes in the expression pattern of epithelial to mesenchymal transition markers, reduced the cells proliferation rate, increased their sensitivity to serum withdrawn, and increased the cytotoxic effect of 5FU. However, significantly higher 5FU cytotoxicity was observed in HT29 cell cultures. Cells with silenced TWIST1 displayed altered expression of enzymes metabolizing 5FU. The expression level of dihydropyrimidine dehydrogenase, and thymidylate synthase decreased significantly in HT29 shTWIST1 cells, but not in HCT116 shTWIST1 cells. On the other hand, significant increases in the expression levels of thymidine phosphorylase, and uridine phosphorylase 1 were seen in both cell lines with suppressed expression of TWIST1. The changes in enzymes expression were mirrored by enzymatic activities. In conclusion, our observations point to TWIST1 as a target protein to enhance the sensitivity of colorectal cancer cells to 5FU.


Subject(s)
Colonic Neoplasms/pathology , Fluorouracil/pharmacology , Gene Silencing , Twist-Related Protein 1/deficiency , Twist-Related Protein 1/genetics , Cell Proliferation/drug effects , Cell Proliferation/genetics , Epithelial-Mesenchymal Transition/drug effects , Epithelial-Mesenchymal Transition/genetics , Fluorouracil/metabolism , Gene Expression Regulation, Neoplastic/drug effects , Gene Expression Regulation, Neoplastic/genetics , HCT116 Cells , HT29 Cells , Humans
5.
Acta Derm Venereol ; 96(4): 459-63, 2016 May.
Article in English | MEDLINE | ID: mdl-26608070

ABSTRACT

There is some evidence that genes involved in the pathogenesis of atopic dermatitis, in addition to the filaggrin (FLG) gene, may be located at chromosome region 1q21. The aim of this study was to examine the association of single nucleotide polymorphisms in the region of the late cornified envelope-like proline-rich 1 (LELP1), hornerin (HRNR) and FLG genes with the course and risk of atopic dermatitis. Single nucleotide polymorphisms and mutations were genotyped by PCR restriction fragment length polymorphism and real-time PCR in a group of 152 patients with atopic dermatitis and 104 healthy volunteers. CC genotype and C-allele of LELP1 rs7534334 were found in patients with atopic dermatitis and were associated with elevated levels of serum immunoglobulin E, severity of atopic dermatitis and concomitant asthma. LELP1 rs7534334 enhanced the risk of atopic dermatitis nearly 2.5-fold. This pilot study suggests that rs7534334 SNP, located in the LELP1 region, may be a potential genetic marker for the risk and course of atopic dermatitis.


Subject(s)
Cornified Envelope Proline-Rich Proteins/genetics , Dermatitis, Atopic/genetics , Polymorphism, Single Nucleotide , Adolescent , Adult , Biomarkers/blood , Case-Control Studies , Child , Dermatitis, Atopic/blood , Dermatitis, Atopic/diagnosis , Female , Filaggrin Proteins , Genetic Association Studies , Genetic Markers , Genetic Predisposition to Disease , Humans , Immunoglobulin E/blood , Male , Middle Aged , Phenotype , Pilot Projects , Risk Factors , Severity of Illness Index , Young Adult
6.
J Surg Oncol ; 112(4): 408-14, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26251082

ABSTRACT

BACKGROUND: Several molecular markers are currently being investigated for their prognostic or predictive value in colorectal cancer. One of the genes proposed, as a potential molecular marker in CRC is CAV1. METHODS: The level of CAV1 expression was investigated in low-stage (I and II TNM) colon cancers using Real-Time PCR and immunohistochemistry. RESULTS: The level of CAV1 expression increased in tumors characterized by greater depths of invasiveness. The CAV1 expression level detected in tumors with a depth of invasion at stage T4 was significantly higher compared to that in T2 (P = 0.01) and T3 (P = 0.003) lesions. The length of a patient's survival depended on CAV1 expression level; the 10-year survival rate for patients with elevated expression of CAV1 was ∼59% compared with 91% for patients with reduced or unchanged expression of CAV1 (P = 0.007). The overall survival rate of patients with T3 + T4 lesions was significantly lower (P = 0.006) for patients with tumor displaying elevated CAV1 expression compared with patients with reduced or unchanged CAV1 expression. CONCLUSIONS: Evaluation of CAV1 expression offers valuable prognostic information for patients with colorectal cancer, and could be used to select patients with stage I or II disease, who are at increased risk of unfavorable outcomes.


Subject(s)
Biomarkers, Tumor/metabolism , Caveolin 1/metabolism , Cell Differentiation , Colon/pathology , Colonic Neoplasms/pathology , Aged , Biomarkers, Tumor/genetics , Case-Control Studies , Caveolin 1/genetics , Colon/metabolism , Colonic Neoplasms/metabolism , Colonic Neoplasms/mortality , Female , Follow-Up Studies , Humans , Immunoenzyme Techniques , Male , Neoplasm Grading , Neoplasm Invasiveness , Neoplasm Staging , Prognosis , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Risk Factors , Survival Rate
7.
Int J Biochem Cell Biol ; 57: 35-44, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25310903

ABSTRACT

Several lines of evidence suggest that a tympanosclerotic (TMS) lesion often develops secondary to acute and chronic otitis media. Histological findings indicate that fibroblasts and inflammatory cells, including mast cells, play a key role in the tympanosclerotic plaque formation. However, details on the functional characteristics of tympanosclerotic fibroblasts (Fs(TMS)) are scanty. Therefore the aim of our study was to examine the activity of human fibroblasts from tympanosclerotic lesions and to evaluate the influence of stimulated by crosslinking of IgE receptor mast cells (HMC-1(FcɛRI)) on fibroblast functional behavior. We observed that fibroblasts from normal tympanic membrane (Fs(TM)) released less TNF-α, TGF-ß1 and IL-6 compared to Fs(TMS). Fs(TMS) but not Fs(TM) upon interaction with HMC-1(FcɛRI) released increased quantities of TNF-α and TGF-ß1. Exposing the fibroblast to HMC-1(FcɛRI) cells resulted in an increased synthesis of proteins including collagen. We noted that the COL2A1 transcript level increased ∼5- and ∼12-fold in Fs(TM) and Fs(TMS) co-cultured with HMC-1(FcɛRI), respectively. Both Fs(TM) and Fs(TMS) upon maintenance in the primary culture released significant quantities of matrix metalloproteinase 9 (MMP-9). However, Fs(TMS) released ∼5-fold more MMP-9 activity compared to the Fs(TM) cultures. The mast cell-induced release of TNF-α, TGF-ß1 and MMP-9 sustained for a longer time in Fs(TMS) cultures compared to Fs(TM). Concluding, our data strongly indicate that increased fibroblast sensitivity to mast cell stimulation greatly contributes to the excessive fibrosis and pathological remodeling of the tympanic membrane. We postulate that the persistency of the Fs(TMS) activated state could be an important factor in the pathogenesis of tympanosclerosis.


Subject(s)
Cell Communication/physiology , Fibroblasts/pathology , Mast Cells/pathology , Myringosclerosis/pathology , Chronic Disease , Collagen/metabolism , Fibroblasts/metabolism , Humans , Mast Cells/metabolism , Matrix Metalloproteinase 9/metabolism , Myringosclerosis/metabolism , Otitis Media/metabolism , Otitis Media/pathology , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL